Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Abstract B026: Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer

Tej Tummala, Arielle De La Cruz, Ash Uruchurtu, Nicholas R Liguori, Abbas E Abbas, Leiqing Zhang, Christopher Azzoli, Lanlan Zhou, Wafik S El-Deiry

Mol Cancer Ther (2023) 22 (12_Supplement): B026.

https://doi.org/10.1158/1535-7163.TARG-23-B026

Published: 01 December 2023

View article titled, Abstract B026: Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer

Journal Articles

Abstract P021: Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results

Brittany A. Borden, Andre De Souza, Devalingam Mahalingam, Steven Powell, Pamela N. Munster, Kelsey Huntington, Andrew Mazar, Ludmila Calvacante, Francis J. Giles, Wafik S. El-Deiry, Howard P. Safran, Benedito A. Carneiro

Mol Cancer Ther (2021) 20 (12_Supplement): P021.

https://doi.org/10.1158/1535-7163.TARG-21-P021

Published: 01 December 2021

View article titled, Abstract P021: Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results

Journal Articles

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer

Isacco Ferrarini, Anna Louie, Lanlan Zhou, Wafik S. El-Deiry

Mol Cancer Ther (2021) 20 (9): 1572–1583.

https://doi.org/10.1158/1535-7163.MCT-20-0962

Published: 01 September 2021

View article titled, ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer

Includes: Supplementary data

Journal Articles

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Brittany A. Borden, Yasmine Baca, Joanne Xiu, Fabio Tavora, Ira Winer, Benjamin A. Weinberg, Ari M. Vanderwalde, Sourat Darabi, W. Michael Korn, Andrew P. Mazar, Francis J. Giles, Lorin Crawford, Howard Safran, Wafik S. El-Deiry, Benedito A. Carneiro

Mol Cancer Ther (2021) 20 (1): 183–190.

https://doi.org/10.1158/1535-7163.MCT-20-0497

Published: 05 January 2021

View article titled, The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Includes: Supplementary data

Journal Articles

Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic

Yiqun Zhang, Lanlan Zhou, Shengliang Zhang, Robyn Borsuk, Howard P. Safran, Attila A. Seyhan, Wafik S. El-Deiry

Mol Cancer Ther (2019) 18 (12_Supplement): LB-C10.

https://doi.org/10.1158/1535-7163.TARG-19-LB-C10

Published: 01 December 2019

View article titled, Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic

Journal Articles

Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment

Isacco Ferrarini, Aakash Jhaveri, Young Lee, Howard Safran, Lanlan Zhou, Wafik S El-Deiry

Mol Cancer Ther (2019) 18 (12_Supplement): LB-C08.

https://doi.org/10.1158/1535-7163.TARG-19-LB-C08

Published: 01 December 2019

View article titled, Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment

Journal Articles

Abstract B092: Assessment of glycogen synthase kinase-3 beta (GSK3β) genomic landscape to inform use of cancer therapeutics

Brittany A. Borden, Lorin Crawford, Howard P. Safran, Francis J. Giles, Wafik S. El-Deiry, Benedito A. Carneiro

Mol Cancer Ther (2019) 18 (12_Supplement): B092.

https://doi.org/10.1158/1535-7163.TARG-19-B092

Published: 01 December 2019

View article titled, Abstract B092: Assessment of glycogen synthase kinase-3 beta (GSK3β) genomic landscape to inform use of cancer therapeutics

Journal Articles

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

Marie D. Ralff, Christina L.B. Kline, Ozan C. Küçükkase, Jessica Wagner, Bora Lim, David T. Dicker, Varun V. Prabhu, Wolfgang Oster, Wafik S. El-Deiry

Mol Cancer Ther (2017) 16 (7): 1290–1298.

https://doi.org/10.1158/1535-7163.MCT-17-0121

Published: 04 July 2017

View article titled, ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

Includes: Supplementary data

Journal Articles

Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells

Marie D. Baumeister, Jessica Wagner, Christina L.B. Kline, Joshua E. Allen, David T. Dicker, Wafik S. El-Deiry

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-A16.

https://doi.org/10.1158/1535-7163.TARG-15-LB-A16

Published: 01 December 2015

View article titled, Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells

Journal Articles

A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus

Yanchun Ma, Sijie Hao, Shuwen Wang, Yuanjun Zhao, Bora Lim, Ming Lei, David J. Spector, Wafik S. El-Deiry, Si-yang Zheng, Jiyue Zhu

Mol Cancer Ther (2015) 14 (3): 835–843.

https://doi.org/10.1158/1535-7163.MCT-14-0693

Published: 09 March 2015

View article titled, A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus

Includes: Supplementary data

Journal Articles

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Nathan G. Dolloff, Joshua E. Allen, David T. Dicker, Nicole Aqui, Dan Vogl, Jozef Malysz, Giampaolo Talamo, Wafik S. El-Deiry

Mol Cancer Ther (2012) 11 (11): 2321–2330.

https://doi.org/10.1158/1535-7163.MCT-12-0578

Published: 08 November 2012

View article titled, Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Includes: Supplementary data

Journal Articles

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

Joshua E. Allen, Roger Ferrini, David T. Dicker, Glenda Batzer, Elise Chen, Daniela I. Oltean, Bing Lin, Mark W. Renshaw, Anke Kretz-Rommel, Wafik S. El-Deiry

Mol Cancer Ther (2012) 11 (10): 2087–2095.

https://doi.org/10.1158/1535-7163.MCT-12-0366

Published: 09 October 2012

View article titled, Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

Includes: Supplementary data

Journal Articles

Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.

Nathan G. Dolloff, Giampaolo Talamo, David T. Dicker, Wafik S. El-Deiry

Mol Cancer Ther (2011) 10 (11_Supplement): C77.

https://doi.org/10.1158/1535-7163.TARG-11-C77

Published: 12 November 2011

View article titled, Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.

Journal Articles

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells

Jay F. Dorsey, Akiva Mintz, Xiaobing Tian, Melissa L. Dowling, John P. Plastaras, David T. Dicker, Gary D. Kao, Wafik S. El-Deiry

Mol Cancer Ther (2009) 8 (12): 3285–3295.

https://doi.org/10.1158/1535-7163.MCT-09-0415

Published: 09 December 2009

View article titled, Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative <em>in vivo</em> effects against glioblastoma multiforme cells

Includes: Supplementary data

NARROW

Abstract B026: Preclinical synergistic combination therapy of lurbinectedin with irinotecan and 5-fluorouracil in pancreatic cancer

Abstract P021: Genomic biomarkers for response to 9-ING-41, a small molecule selective glycogen synthase kinase-3 (GSK-3) inhibitor, in pancreas cancer: Preliminary results

ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer

The Landscape of Glycogen Synthase Kinase-3 Beta Genomic Alterations in Cancer

Abstract LB-C10: Preclinical synergistic anti-tumor effect against multiple cancer types by EZH2 inhibitor EPZ-6438 plus imipridone ONC201 to mimic H3K27M mutation observed in DIPG tumors that respond to ONC201 in the clinic

Abstract LB-C08: Imipridone ONC212 induces apoptosis, suppresses autophagy and synergizes upon GRP132 knockdown or exposure to lactic acid in preclinical studies of the pancreatic cancer microenvironment

Abstract B092: Assessment of glycogen synthase kinase-3 beta (GSK3β) genomic landscape to inform use of cancer therapeutics

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells

A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

Abstract C77: Sangivamycin-like molecule 6 (SLM6) exhibits potent and selective anti-multiple myeloma activity through inhibition of P-TEFb.

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only